Recent Finacing
Recent Raise
Pearl Therapeutics, based in Redwood City, develops inhaled combination therapies for COPD and asthma, including PT003 (glycopyrrolate plus formoterol) delivered via HFA MDI and particle-targeting technology.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors